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1190A Pharmacokinetic Model for Protamine Dosing
lmonary BypassMichael I. Meesters, MD,* Dennis Veerhoek, CCP,† Jan R. de Jong, MD,* and Christa Boer, PhD*Objective: This study investigated postoperative hemo-
stasis of patients subjected to conventional protamine
dosing compared with protamine dosing based on a phar-
macokinetic (PK) model following cardiopulmonary bypass.
Design: Retrospective case-control study.
Setting: Tertiary university hospital.
Participants: Patients undergoing elective cardiac surgery
with cardiopulmonary bypass.
Interventions: In 56 patients, protamine was dosed in a
ﬁxed ratio (CD), while 62 patients received protamine based
on the PK model.
Measurements and Main Results: There was no difference
in heparin administration (414  107 mg (CD) v 403  90 mg
(PK); p ¼ 0.54), whereas protamine dosing was considerably
different with a protamine-to-heparin dosing ratio of 1.1  0.3
for the CD group and 0.5  0.1 for the PK group (po 0.001). The
changes in activated coagulation time (ΔACT) values (ACT after
protamine minus preoperative ACT; þ17  77 s v þ6  15 s;of *Anesthesiology; and †Cardio-thoracic
diovascular Research, VU University Medical
Netherlands.
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Journal of Cardiothoracicp ¼ 0.31) were equal between groups. Yet, the thromboelasto-
metric intrinsically activated coagulation test clotting time (CT;
250  76 s v 203  44 s; po 0.001) and intrinsically activated
coagulation test without the heparin effect CT (275  105 v
198  32 s; po 0.001) were prolonged in the CD group. Median
packed red blood cell transfusion (0 [0–2] v 0 [0–0]), fresh frozen
plasma transfusion (1 [0–2] v 0 [0–0]), and platelet concentrate
transfusion (0 [0–1] v 0 [0–0]) were different between the ﬁxed
ratio and PK group, respectively (all po 0.001).
Conclusions: This study showed that patient-tailored
protamine dosing based on a PK model was associated with
a reduction in protamine dosing, with better hemostatic test
results when compared with ﬁxed-ratio protamine dosing.
& 2016 The Authors. Published by Elsevier Inc. All rights
reserved.
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cardiopulmonary bypass, hemostasis, coagulationPROTAMINE IS USED to reverse heparin after terminationof cardiopulmonary bypass (CPB). The anticoagulant
properties of heparin are antagonized by the formation of a
neutral 1:1 protamine-heparin complex. Protamine is com-
monly administered in a ﬁxed protamine-to-heparin ratio based
on the intraoperative dose of heparin, irrespective of the
patient’s heparin consumption. Protamine dosing usually
ranges from 0.5 to 1.3 mg of protamine per 100 IU of heparin
administrated.1,2
Yet, during CPB, heparin is broken down, with a half-life of
approximately 4 hours in high dosage, and a small part of
heparin is lost by blood loss. When these factors were taken
into account, protamine dosing based on a ﬁxed ratio was
inadequate for the great majority of patients, and might lead to
unantagonized heparin or protamine overdose, both causing
coagulopathy.3,4
An alternative method for individualized protamine
dosing is heparin and protamine administration using a
point-of-care hemostasis management system.5 The heparin
concentration is estimated in vitro and multiplied by the
calculated blood volume of the patient, leading to an
advised protamine dosage. This method has been shown tocontribute to individualized protamine dosing; however, the
technique is costly. Therefore, its additive value and cost-
beneﬁt for its use in routine minor and moderate risk cardiac
surgery is debatable.
In order to offer an alternative for the titration method
the authors developed a two-compartment pharmacokinetic
(PK) model that estimates the heparin blood concentration
from the administered heparin doses and time of admin-
istration to calculate the loss of heparin over time.6 By
estimating the amount of heparin at the end of CPB, the
required protamine dosage is calculated to neutralize
heparin. In this study the authors investigated if imple-
mentation of this PK model improved clinical practice by
evaluating postoperative bleeding, blood transfusion, and
hemostasis by thromboelastometry.
METHODS
Study Population
This retrospective observational study was performed in the
Departments of Anesthesiology and Cardiothoracic Surgery of
the VU University Medical Center (Amsterdam, The Nether-
lands). Two cohorts were compared, before and after the
implementation of the PK protamine dosing. All measurements
were part of routine clinical practice. The local Human Subjects
Committee approved this retrospective analysis (METc 2012/
438) and waived informed consent. During the study period no
alterations were made in the perioperative cardiac surgery
practice. Additionally, there were no changes in the dedicated
anesthesia or cardiothoracic surgery team.
Patients aged 18 to 85 years were eligible if they were
scheduled for elective cardiac surgery with CPB. Acetylsa-
licylic acid was not discontinued prior to surgery, whereas
clopidogrel was stopped 5 days prior to the cardiac proce-
dure. Exclusion criteria were emergency surgery, a body
mass index below 18 kg/m2 or above 35 kg/m2, a history of
hematologic disorders, the necessity for renal replacementand Vascular Anesthesia, Vol 30, No 5 (October), 2016: pp 1190–1195
Fig 1. Schematic representation of the pharmacokinetic heparin
model. Prior to CPB a bolus of 300 IE/kg of heparin is administered to
achieve an ACT4480 s. During CPB, when the heparin concentration
drops due to its half-life, the ACT will shorten. When the ACT falls
below 480 seconds an additional bolus of heparin is administered,
resulting in a second peak concentration of heparin in the blood.
CPB, cardiopulmonary bypass; ACT, activated coagulation time.
PROTAMINE DOSING AFTER CPB 1191therapy, and the preoperative use of heparin or heparin-like
medication.
Study Procedure
The ﬁrst cohort of patients received protamine based on a
ﬁxed ratio at the discretion of the attending anesthesiologist.
The second cohort received protamine based on a two-
compartment model to estimate the heparin concentration in
blood (Fig 1). The calculated residual heparin concentration
was multiplied by the calculated blood volume, resulting in the
residual amount of heparin. Protamine was dosed in a 1:1 ratio
based on the calculated amount of residual heparin after
termination of CPB.
Protamine Dosing Model
A two-compartment model was implemented using the
following equation:
Ct’¼C0:A:eαtþC0:B:eβt
Ct is the residual heparin in the patient at the moment of
protamine dosing (t). A and B represent the distribution over
the subsequent compartments of the initial dose (C0), 0.1 and
0.9, respectively,7 and e is the base of the natural logarithm
(2.718) with α and β being the time constants of both
compartments (α ¼ 10 minutes and β ¼ 250 minutes). The
half-life of heparin increases by incremental dosage. The
highest dose investigated was 400 IU and showed a half-life
of 150 minutes in humans.8 Patients receive an average of 500
IU of heparin during a cardiac procedure in this center, leading
to a half-life greater than 150 minutes. The half-life is expected
to increase further with cooling (to approximately 34oC during
CPB). As the detrimental effect of heparin overdosing is greater
than protamine overdosing, the half-life of heparin was rounded
up to avoid a residual heparin effect. In the absence of evidence
about the half-life of high-dose heparin during CPB, anempirical half-life (β) of 250 minutes was chosen taking all
the above-mentioned factors into consideration.
The ﬁnal dose of protamine was calculated combining the
remainder of the initial bolus (Ct’) plus the remainder of the
subsequent bolus (Ct”, Ct”’…). Protamine was dosed in a 1:1
ratio with the calculated remainder of heparin (mg).
Anesthesia and Cardiopulmonary Bypass
Patients were anesthetized according to local protocols
based on a combination of sufentanil, 3-7 μg/kg, rocuronium,
0.6 mg/kg, and midazolam, 0.1 mg/kg, for anesthesia induction
and tracheal intubation. Propofol (200-400 μg/hour), with or
without isoﬂurane/sevoﬂurane, was used for maintenance of
anesthesia. All patients received tranexamic acid (1 gram prior
to and 2 gram after CPB).
CPB was performed at a blood ﬂow of (2.2-2.4 L/min/m2)
during normo- or mild hypothermia (434oC) using either
a C5 or S5 heart–lung machine (Stöckert Instrumente GMBH,
Munich, Germany) with a centrifugal pump and biocompatible
coated circuit. Cell saving was applied throughout the surgical
procedure. Shed blood from the thoracic cavity and residual
blood that remained in the extracorporeal system after bypass
were sucked up into the cell-saver reservoir using a dual-lumen
tube connected to a vacuum pump, and subsequently trans-
ferred to the centrifuge bowl of the cell saver (Autolog,
Medtronic, Minneapolis, MN). After plasma removal, red
blood cells were washed, and concentrated red blood cells
were retransfused.
Heparin and Protamine Management
Heparinization started with an initial bolus of 300 IU/kg of
heparin (LEO Pharma BV, Amsterdam, The Netherlands) to
achieve an activated coagulation time (ACT) test of 480
seconds. If necessary, additional doses of heparin (5000 IU)
were administered to maintain this target ACT. The priming
solution (1200 mL) contained 5000 IU of heparin.
After weaning from CPB, heparin was reversed with prot-
amine hydrochloride (MedaPharma BV, Amstelveen, The
Netherlands). The amount of protamine in the ﬁrst cohort
was at the discretion of the attending anesthesiologist in a ﬁxed
ratio. After implementation of the PK-based protamine dosing
model, the second cohort was evaluated.
Local Blood Transfusion Algorithm
The transfusion of packed red blood cells (PRBC) was
based on the Dutch transfusion guidelines, recommending
transfusion if hemoglobin levels are below 9.7 g/dL (6 mmol/
L), in American Society of Anesthesiologists IV patients, and
patients with symptomatic cerebrovascular disease, sepsis,
heart failure, or severe pulmonary disease. Packed red blood
cells transfusion is advised in cases of hemoglobin levels below
8.1 g/dL (5 mmol/L), in cases of acute blood loss from one
bleeding focus in a normovolemic American Society of
Anesthesiologists I patient aged460 years, and in cases of
fever or following cardiac surgery. Fresh frozen plasma
or platelet transfusion was performed in patients with clinical
signs of persistent nonsurgical bleeding (oozing). When
laboratory coagulation test results were available, fresh frozen
Table 1. Patient Demographics and Surgical Characteristics
CD PK p Value
N 56 62
Age (years) 66  12 67  11 0.74
BMI (kg/m2) 28  4 27  4 0.61
Males (n [%]) 30 (54%) 47 (76%) 0.02
Preoperative anticoagulation
Acetylsalicylic acid (n) 20 (36%) 32 (52%) 0.07
Clopidogrel (n) 1 (2%) 8 (13%) 0.02
Heparin (n) 2 (4%) 4 (7%) 0.46
ECC time (min) 132  53 117  44 0.09
Aorta clamp time (min) 98  41 85  35 0.07
Lowest temperature (oC) 34  1 34  1 0.10
Lowest hemoglobin 0.79
mmoL/L 5.3  1.0 5.3  0.8
g/dL 8.5  1.6 8.5  1.3
Type of surgery o0.001
CABG (n) 6 (11%) 31 (51%)
Valve surgery (n) 29 (51%) 16 (26%)
CABG þ valve (n) 18 (32%) 11 (18%)
Bentall  CABG (n) 3 (5%) 2 (3%)
NOTE. Data represent frequencies or mean  standard deviation.
Abbreviations: BMI, body mass index; CABG, coronary artery
bypass graft; CD, conventional dosing; ECC, extracorporeal circula-
tion; PK, pharmacokinetic dosing.
Fig 2. Protamine and heparin dosage. The protamine-to-heparin
dosing ratio resulted in 1.1  0.3 for the CD, and 0.5  0.1 for the PK
dosing (p o 0.001). PK, pharmacokinetic dosing.
MEESTERS ET AL1192plasma was transfused when the international normalized ratio
of the prothrombin time exceeded 1.5. Additional platelet
concentrate administration was indicated for extended bypass
times, clinical signs of bleeding, and/or a platelet count below
75109/L.
Blood Sampling
After anesthesia induction, the ﬁrst blood sample was
collected for hemostatic baseline evaluation as part of routine
practice. Blood was drawn in a citrated tube from the radial
artery catheter. Three minutes after protamine administration
another blood sample was drawn for routine hemostatic
evaluation.
Thromboelastometry
Using rotational thromboelastometry (ROTEM delta; TEM
International, Munich, Germany), the viscoelastic properties of
a blood clot were measured in vitro using the intrinsically
activated coagulation test (INTEM), extrinsically activated
coagulation test (EXTEM), ﬁbrin polymerization test, and the
intrinsically activated coagulation test without the heparin
effect (HEPTEM). Clot formation was assessed by the clotting
time or the maximum clot ﬁrmness (MCF), which were
represented in a thromboelastogram.
Other Study Parameters
Patient demographics included age, gender, and body mass
index. Collected surgical data were CPB time, aortic cross-
clamp time, and the amount of heparin and protamine
administered. Hemostatic parameters included pre- and post-
operative prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), ACT, hemoglobin concentration, and
platelet count. Clinical outcomes included blood loss assessedat 6, 12, and 24 hours by chest drainage and postoperative
allogeneic blood transfusion.
Statistical Analysis
Statistical analysis was performed using the SPSS statistical
software package 22.0 (SPSS Inc.s, IBM, New York).
Descriptive statistics are presented as frequencies (nominal
data), median with interquartile range (non-parametric data), or
mean with standard deviation (numerical data). A Student’s
T-test, Mann–Whitney U test, or chi-square test was used for
differences in numeric, ordinal, or nominal data, respectively,
between the cohorts. Multiple linear regression was performed to
evaluate the possible confounding effect of the type of surgery
on thromboelastometric results, and postoperative blood loss
for both groups, as this was different between groups.
A p valueo 0.05 was considered as statistically different.
RESULTS
The study population included 118 patients undergoing
cardiac surgery with CPB. The conventional dosing (CD)
cohort consisted of 56 patients, and 62 patients received
protamine dosing according to the PK model. Table 1 shows
patient and surgical characteristics for both patient cohorts.
There were no differences in patient demographics between
groups, except for a higher proportion of male patients in the
PK group.
Figure 2 shows heparin and protamine dosing in the CD and
PK dosing groups. Implementation of the PK model did not
alter heparin dosing, but signiﬁcantly reduced protamine dosing
from 416  82 mg to 186  42 mg (p ¼ 0.001) compared
with the CD group. This resulted in a major reduction in the
protamine-to-heparin dosing ratio from 1.1  0.3 for the CD to
0.5  0.1 for the PK dosing (po 0.001).
Table 2 shows whether reduced protamine dosing in the PK
group was associated with alterations in patient hemostasis,
differences for hemoglobin, aPTT, prothrombin time, and
platelet count between groups before surgery and at 3 minutes
following protamine administration. Figure 3 shows the throm-
boelastometric clotting times for the subsequent tests 3 minutes
after protamine administration. Furthermore, INTEM MCF was
Table 2. Laboratory Findings
CD PK p Value
Preoperative
Hemoglobin o0.001
mmol/l 8.1  0.9 8.8  1.0
g/dl 13.0  1.4 14.1  1.6
aPTT (s) 37  6 38  8 0.50
PT (INR) 1.2  0.4 1.1  0.6 0.73
Platelet count (109/l) 245  59 233  73 0.38
3 min after protamine
Hemoglobin o0.01
mmol/l 6.1  0.9 5.7  0.7
g/dl 9.8  1.4 9.1  1.1
PT (INR) 1.9  0.5 1.6  0.2 o0.001
Platelet count (109/L) 109  35 129  39 o0.01
aPTT (s) after protamine
3 min 42  13 43  5 0.73
1 h 41  8 42  7 0.35
2 h 39  7 39  9 0.99
ACT
ACT preoperative (s) 131  15 124  15 0.01
ACT after protamine dosing (s) 148  74 130  13 0.08
Delta ACT (postop – preop) þ 17  77 þ 6  15 0.31
NOTE. Data represent frequencies or mean  standard deviation.
Abbreviations: ACT, activated coagulation time; aPTT, activated
partial thrombin time; CD, conventional dosing; INR, international
normalized ratio; PK, phramacokinetic dosing; PT, prothrombin time.
Table 3. Postoperative Outcome
CD PK p Value
Postoperative transfusion
PRBC 0 (0-2) 0 (0-0) o0.001
0 units (n [%]) 27 (52%) 58 (93%)
1-2 units (n [%]) 13 (25%) 3 (5%)
Z 3 units (n [%]) 12 (23%) 1 (2%)
Fresh frozen plasma 1 (0-2) 0 (0-0) o0.001
0 units (n [%]) 26 (50%) 61 (98%)
1-2 units (n [%]) 17 (32%) 1 (2%)
Z 3 units (n [%]) 9 (18%) 0 (0%)
Platelet concentrate 0 (0-1) 0 (0-0) o0.001
0 units (n [%]) 27 (52%) 59 (95%)
1-2 units (n [%]) 23 (44%) 3 (5%)
3 units (n (%)) 2 (4%) 0 (0%)
Fibrinogen concentrate 0 (0-0) n¼3 0 (0-0) n¼4 0.98
Prothrombin complex concentrate 0 (0-0) n¼1 0 (0-0) n¼8 0.48
NOTE. Data are represented as median with interquartile range.
Abbreviations: CD, conventional dosing; PK, pharmacokinetic dos-
ing; PRBC, packed red blood cells.
PROTAMINE DOSING AFTER CPB 119352  8 in the CD group compared with 59  9 in the PK
dosing group, po 0.01. EXTEM MCF was higher in the PK
group (60  9) when compared with the CD group (54  8, p
¼ 0.02), respectively. The ﬁbrin part of the clot (ﬁbrin
polymerization test MCF) was 11  4 in the CD group and
14  6 in the PK group, p ¼ 0.01.
There was a difference in median postoperative blood loss 6
hours after surgery (110 [73;228)] v 180 [121,292] mL, p ¼
0.01), yet there was no difference at 12 hours (248 [141:375] vFig 3. Thromboelastometric test results at three minutes follow-
ing protamine administration. PK, pharmacokinetic dosing; INTEM,
intrinsic coagulation cascade; HEPTEM, intrinsic coagulation cascade
in the presence of heparinase; EXTEM, extrinsic coagulation cascade.
*po 0.05.250 [180,329] mL, p4 0.34) nor 24 hours after surgery (340
[242,525] v 387 [293,548] mL, p4 0.27) for the conventional
versus the PK dosing group. Table 3 shows the postoperative
transfusion outcome for both groups.
Multiple Linear Regression
Multiple linear regression was performed to evaluate the
possible confounding effect of the type of surgery on throm-
boelastometric results and postoperative blood loss for both
groups (Tables S1 and S2). The effect of PK dosing remained
signiﬁcant after correcting for the type of surgery for the
INTEM, and HEPTEM was improved by PK dosing after
correcting for the type of surgery when compared with the CD
group. There were no differences in EXTEM or postoperative
blood loss 6 hours postoperative after correcting for the type of
surgery.
DISCUSSION
Protamine dosing based on a PK model for residual heparin
after CPB was associated with a reduction of more than 50% of
the protamine dose when compared with a conventional ﬁxed
protamine-to-heparin dosing strategy with full neutralization of
the postoperative ACT. This reduction in protamine admin-
istration was paralleled by better postoperative hemostasis, less
allogeneic blood transfusion, and might reduce postoperative
blood loss when compared with the control cohort. This study
suggested that patient-tailored protamine administration based
on the concentration of residual heparin was beneﬁcial for
patient hemostasis following cardiac surgery with CPB.
Several studies have shown that unbound protamine has
intrinsic anticoagulant properties that may impair hemostasis.
Nielsen and Malayaman previously gave an overview of the
negative effects of protamine on hemostasis, showing that
protamine decreases thrombin (factor IIa) activity, reduces
factor VII and V activation, enhances ﬁbrinolysis, and impairs
platelet function by inhibition of GPIb-vWF activity.4 The
complex balance between protamine underdosing, which may
MEESTERS ET AL1194result in residual heparin, and protamine overdosing, which
may result in impaired hemostasis, warrants better tools for
protamine dosing.
More than half a century ago the ﬁrst attempts to optimize
protamine dosing were made.9 Since then there have been
studies showing that a protamine dose reduction led to better
outcomes.10,11 A more recent development was the introduc-
tion of protamine titration, which also showed a (minor)
reduction of postoperative blood loss.12 Yet, so far it is
common practice that protamine is dosed based on a ﬁxed
ratio to heparin, with adjustments based on the clinical
experience of the anesthesiologist. Current guidelines advise
a protamine-to-heparin dosing ratio of 1:1 to 1:1.3, with a level
IIb recommendation for lower protamine dosing.1,2 As heparin
is lost during CPB, a ratio of 1 mg of protamine for every
milligram of heparin administered could result in protamine
overdosing and impairment of hemostasis.
An alternative to a ﬁxed protamine-dosing regimen is pro-
tamine titration, a method that titrates protamine ex vivo to ﬁnd
the optimal protamine-to-heparin dosing ratio. A meta-analysis
by Wang et al showed that protamine titration might improve
protamine dosing in cardiac surgery.12 However, the meta-
analysis was limited to the inclusion of studies not designed for
comparison of protamine titration, and studies with a small
sample size. Further attempts to improve protamine dosing
were based on the perioperative anti-Xa or heparin concen-
tration, the ACT or thrombin assay.13-15 Unfortunately, none of
these attempts resulted in major improvement of perioperative
protamine management.
Recently, several groups have developed mathematical
models for protamine dosing. Jia et al established a PK model
to predict heparin concentrations during cardiac surgery,
suggesting a lower protamine dosing regimen after termination
of CPB.16 Davidsson and colleagues developed another sta-
tistical model for protamine dosing and showed a good
agreement with point-of-care protamine dosing.17 Finally,
Kjellberg et al built a protamine dosing algorithm and reduced
protamine dosing without any signiﬁcant difference inpostoperative bleeding.18 Yet, these authors were the ﬁrst to
develop a PK model for protamine dosing leading to reduced
protamine dosing, improved postoperative hemostasis, and less
blood loss 6 hours after surgery when compared with conven-
tional protamine dosing.
Protamine generally is overdosed in cases of elevated ACT
levels to neutralize residual circulating heparin, neglecting the
possible detrimental effect of protamine overdosing. Interest-
ingly, the PK dosing group showed a trend towards lower
postoperative ACT values and no difference in aPTT, which is
more sensitive for residual heparin,19 when compared with the
CD group. Another concern is postoperative “heparin
rebound”, the reappearance of circulating heparin after neutral-
ization with protamine. Yet, a recent study suggested that this
phenomenon might be a minor contributing factor to post-
operative bleeding.20 Additionally, the authors did not ﬁnd any
evidence of heparin rebound in the PK dosing group, as there
was no difference in sequential postoperative aPTT values after
surgery.
This study was limited by its retrospective design and the
relatively small sample size per patient cohort. Because the two
cohorts were sequential, the possibility of a chronology bias
cannot be excluded. Furthermore, the absence of heparin
measurements limits insight in the accuracy of the PK model,
and the postoperative abundance of heparin or protamine.
Moreover, the lack of repetitive heparin measurements follow-
ing surgery limited the conclusions about the effect of the
protamine dosing method on the occurrence of heparin
rebound. Despite the limitations of this study, the beneﬁts of
PK-based protamine administration for postoperative hemo-
stasis and allogeneic blood transfusion requirements warrant
further exploration of patient-tailored heparin and protamine
administration in cardiac surgery with CPB.APPENDIX A. SUPPLEMENTARY MATERIAL
Supplementary data associated with this article can be found in
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